Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBS303 in relapsed/refractory B-cell NHL
NCT05806099Phase 2Recruiting
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- Jun 2023
- Primary completion
- Nov 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MBS303 in B-cell non-Hodgkin lymphoma, sponsored by Beijing Tianguangshi Pharmaceutical Technology. Primary endpoints: Percentage of Participants with Adverse Events (AEs), Incidence of Dose Limiting Toxicities (DLTs) at 3 weeks and 3 more. Started Jun 2023; status: recruiting.
02
Drugs
MBS303
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05806099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05806099.